The U.S. Food and Drug Administration has approved Lynkuet, a new medication that does not contain hormones to treat hot ...
Eli Lilly reports new data showing sustained efficacy for Ebglyss with less frequent dosing and strong long-term results for ...
The drug, elinzanetant, is expected to be available in the United States beginning in November under the brand name Lynkuet, ...
Belantamab mafodotin, a BCMA-targeting ADC, is approved for relapsed/refractory multiple myeloma after two prior therapies, ...
Syndax Pharmaceuticals, Inc. ( NASDAQ: SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia October 24, 2025 2:30 PM EDT ...
Novo Nordisk (($NVO)) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is conducting a post-marketing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback